Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma

Clinical Cancer Research

Volumn 15, Issue 6, 2009, Pages 1998-2009

  Labrinidis, Agatha ^a   Diamond, Peter ^b   Martin, Sally ^b   Hay, Shelley ^a   Liapis, Vasilios ^a   Zinonos, Irene ^a   Sims, Natalie A ^c   Atkins, Gerald J ^a   Vincent, Cristina ^a   Ponomarev, Vladimir ^d   Findlay, David M ^a   Zannettino, Andrew C W ^b   Evdokiou, Andreas ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b HANSON INSTITUTE   (Australia)

^c ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; LUCIFERASE; OSTEOPROTEGERIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; THYMIDINE KINASE; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BONE DESTRUCTION; BONE MARROW; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; NUDE MOUSE; OSTEOLYSIS; PRIORITY JOURNAL; REPORTER GENE;

ANIMALS; BONE AND BONES; CELL DIFFERENTIATION; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; OSTEOCLASTS; OSTEOLYSIS; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSPLANTATION, HETEROLOGOUS;

EID: 63549135868     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2444     Document Type: Article

References (46)

1. Croucher PI, Apperley JF. Bone disease in multiple myeloma. Br J Haematol 1998;103:902-10.
2. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111:2962-72.
3. Zannettino AC, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal-derived factor-1 α are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 2005;65:1700-9.
4. Farrugia AN, Atkins GJ, To LB, et al. Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003;63:5438-45.
5. Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jakob C, Sezer O. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem Biophys Res Commun 2005;338:687-93.
6. Bouralexis S, Findlay DM, Evdokiou A. Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 2005;10:35-51.
7. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30.
8. Vitovski S, Phillips JS, Sayers J, Croucher PI. Investigating the interaction between osteoprotegerin and receptor activator of NF-κB or tumor necrosis factorrelated apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 2007;282:31601-9.
9. Truneh A, Sharma S, Silverman C, et al. Temperature sensitive differential affinity ofTRAIL for its receptors: DR5 is the highest affinity receptor. J Biol Chem 2000;275:23319-25.
10. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003;63:912-6.
11. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363-7.
12. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosisinducing ligand in vivo. Nat Med 1999;5:157-63.
13. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
14. Atkins GJ, Bouralexis S, Evdokiou A, et al. Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone 2002;31:448-56.
15. Butler LM,Liapis V,BouralexisS,et al. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer 2006; 119:944-54.
16. GriffithTS, ChinWA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998;161: 2833-40.
17. Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186:1165-70.
18. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999;59: 734-41.
19. Zhang XD, FrancoAV, Nguyen T, Gray CP, Hersey P. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 2000;164:3961-70.
20. Zhang XD, Nguyen T,Thomas WD, Sanders JE, Hersey P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 2000;482:193-9.
21. Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms ofTRAIL: apoptosis through mitochondrial-dependent and-independent pathways. Oncogene 2001;20:2122-33.
22. Kelley SK, Harris LA, Xie D, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis inducing ligand in humans:characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol ExpTher 2001;299:31-8.
23. Jin H, Yang R, Fong S, et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 2004;64:4900-5.
24. Roth W, Isenmann S, Naumann U, et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999;265:479-83.
25. Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A 2000;97: 1754-9.
26. Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999;59:6153-8.
27. Pan Y. Application of pharmacodynamic assays in a phase 1a trial of Apo2L/TRAIL in patients with advanced tumours [abstract 3535]. J Clin Oncol (ASCO) 2007;25:3535.
28. Yee L. A phase 1B safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma [abstr 8078]. J Clin Oncol (ASCO) 2007;25:8078.
29. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/ Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001;98:795-804.
30. PonomarevV, Doubrovin M, Serganova I, etal. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging 2004;31:740-51.
31. Zannettino AC, Rayner JR, Ashman LK, Gonda TJ, Simmons PJ. A powerful new technique for isolating genes encoding cell surface antigens using retroviral expression cloning. J Immunol 1996;156:611-20.
32. Berlin O, Samid D, Donthineni-Rao R, Akeson W, Amiel D, Woods VL. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted or thotopically into bone of athymic mice. Cancer Res 1993;53:4890-5.
33. Thai le M, Labrinidis A, Hay S, et al. Apo2L/tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model. Cancer Res 2006;66:5363-70.
34. Sims NA, Brennan K, Spaliviero J, Handelsman DJ, Seibel MJ. Perinatal testosterone surge is required for normal adult bone size but not for normal bone remodeling. Am J Physiol Endocrinol Metab 2006; 290:E456-62.
35. Sims NA, Clement-Lacroix P, Da Ponte F, et al. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest 2000;106:1095-103.
36. Zauli G, Rimondi E, Stea S, et al. TRAIL inhibits osteoclastic differentiation by counteracting RANKL dependent p27Kip1 accumulation in pre-osteoclast precursors. J Cell Physiol 2008;214:117-25.
37. Zauli G, Rimondi E,Nicolin V, Melloni E,Celeghini C, Secchiero P. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 2004;104:2044-50.
38. Roux S, Lambert-Comeau P, Saint-Pierre C, Lepine M, Sawan B, Parent JL. Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Biochem Biophys Res Commun 2005; 333:42-50.
39. Labrinidis A, LiapisV,Thai le M, et al. Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis? Blood 2008;111:5411-2.
40. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/ TRAIL versions. Nat Med 2001;7:383-5.
41. Adams C, Totpal K, Lawrence D, et al. Structural and functional analysis of the interaction between the agonistic and monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008; 15:751-6.
42. Pacey S, Plummer RE, Attard G,et al. Phase 1 and pharmacokinetic study of HGS-E TR2, a human monoclonal antibody to TRAIL-R2, in patients with advanced solid malignancies [abstract B114]. AACRNCI-EORTC International Conference on Molecular Targets and Cancer Therapies; Philadelphia, PA; 2005.
43. Camidge D, Herbst RS, Gordon M, et al. A phase 1 safety and pharmacokinetic study of Apomab, a human DR5 agonistic antibody, in patients with advanced cancer [abstract]. Proc ASCO 2007;25: 3582.
44. Hotte SJ, HirteHW, Chen EX, etal. HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: results of a phase1trial [abstract]. Proc ASCO 2005;23:3052.
45. Sikic BI,Wakelee HA, von Mehren M, et al. A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activatesTRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI [abstract]. Proc ASCO 2007;25: 14006.
46. Tolcher AW, Mita M, Meropol NJ, et al. Phase 1 pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonistic activity to tumour necrosis factorrelated apoptosis-inducing ligand receptor-1. J Clin Oncol 2007;25:1390-5.